DK4034535T3 - Aza-quinolinforbindelser og anvendelser deraf - Google Patents

Aza-quinolinforbindelser og anvendelser deraf

Info

Publication number
DK4034535T3
DK4034535T3 DK20868772.3T DK20868772T DK4034535T3 DK 4034535 T3 DK4034535 T3 DK 4034535T3 DK 20868772 T DK20868772 T DK 20868772T DK 4034535 T3 DK4034535 T3 DK 4034535T3
Authority
DK
Denmark
Prior art keywords
aza
quinoline compounds
quinoline
compounds
Prior art date
Application number
DK20868772.3T
Other languages
Danish (da)
English (en)
Inventor
Xuan Dai
Michael Dore
Xiang-Ju Justin Gu
Kevin Kun Chin Liu
Sing Yeung Frankie Mak
Yuan Mi
Counde Oyang
Julien Papillon
Wei Qi (Vicky)
Xiaoxia Yan
Zhengtian Yu
Ji Yue Zhang (Jeff)
Kehao Zhao
Ling Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK4034535T3 publication Critical patent/DK4034535T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK20868772.3T 2019-09-26 2020-09-24 Aza-quinolinforbindelser og anvendelser deraf DK4034535T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019108296 2019-09-26
PCT/CN2020/117487 WO2021057853A1 (en) 2019-09-26 2020-09-24 Aza-quinoline compounds and uses thereof

Publications (1)

Publication Number Publication Date
DK4034535T3 true DK4034535T3 (da) 2026-04-07

Family

ID=75166744

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20868772.3T DK4034535T3 (da) 2019-09-26 2020-09-24 Aza-quinolinforbindelser og anvendelser deraf

Country Status (10)

Country Link
US (2) US12544374B2 (https=)
EP (1) EP4034535B1 (https=)
JP (1) JP7763753B2 (https=)
KR (1) KR102889562B1 (https=)
CN (1) CN114746414B (https=)
AU (1) AU2020355837B2 (https=)
CA (1) CA3150284A1 (https=)
DK (1) DK4034535T3 (https=)
IL (1) IL291499B2 (https=)
WO (1) WO2021057853A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7763753B2 (ja) 2019-09-26 2025-11-04 ノバルティス アーゲー アザキノリン化合物およびその使用
AR123185A1 (es) * 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
AU2022412837A1 (en) * 2021-12-16 2024-06-13 Teijin Pharma Limited Cdk9 inhibitor and use thereof
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
CN118515653B (zh) * 2024-07-23 2024-12-10 西湖制药(杭州)有限公司 一种ezh2特异性抑制剂及其制备方法和用途
CN118598873B (zh) * 2024-08-07 2024-11-19 艾斯拓康生物医药(天津)有限公司 一种手性的氮杂-喹啉类化合物的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
EP1143957A3 (en) 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors
JP3811775B2 (ja) 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 4−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
CN1653059A (zh) 2002-03-08 2005-08-10 卫材株式会社 用作医药品的大环化合物
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Mek 억제제로서의 n3 알킬화 벤즈이미다졸 유도체
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2205242B1 (en) 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック, インコーポレイテッド チエノピリミジン化合物の製造方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
WO2014155301A1 (en) 2013-03-26 2014-10-02 Piramal Enterprises Limited Substituted bicyclic compounds as inhibitors of ezh2
UY36462A (es) 2014-12-23 2016-07-29 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos
UY36758A (es) 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homólogo zeste 2
WO2017221092A1 (en) 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
EP3472166A1 (en) 2016-06-20 2019-04-24 Novartis AG Imidazopyrimidine compounds useful for the treatment of cancer
KR20190084063A (ko) 2016-10-28 2019-07-15 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Ezh2-매개성 암 치료용 조성물 및 방법
JP7763753B2 (ja) 2019-09-26 2025-11-04 ノバルティス アーゲー アザキノリン化合物およびその使用

Also Published As

Publication number Publication date
IL291499A (en) 2022-05-01
KR20220070229A (ko) 2022-05-30
CA3150284A1 (en) 2021-04-01
AU2020355837B2 (en) 2025-10-02
EP4034535A1 (en) 2022-08-03
JP2022550353A (ja) 2022-12-01
IL291499B2 (en) 2025-08-01
CN114746414A (zh) 2022-07-12
JP7763753B2 (ja) 2025-11-04
US20220280509A1 (en) 2022-09-08
IL291499B1 (en) 2025-04-01
US12544374B2 (en) 2026-02-10
WO2021057853A1 (en) 2021-04-01
CN114746414B (zh) 2024-10-18
EP4034535A4 (en) 2023-11-22
KR102889562B1 (ko) 2025-11-24
AU2020355837A1 (en) 2022-02-24
EP4034535B1 (en) 2026-03-04
US20260076968A1 (en) 2026-03-19

Similar Documents

Publication Publication Date Title
IL285178A (en) Compounds and uses thereof
DK3917616T3 (da) Heterocykliske forbindelser og anvendelse deraf
DK3946464T3 (da) Forbindelser og konjugater deraf
IL285461A (en) Processes and compounds
IL282998A (en) Pyridazinone compounds and uses thereof
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
IL278122B1 (en) Pteridinone compounds and uses thereof
DK4196479T3 (da) Substituerede pyridotriazinforbindelser og anvendelser deraf
DK4034535T3 (da) Aza-quinolinforbindelser og anvendelser deraf
EP3930851A4 (en) COMBINATION THERAPIES
EP3919491C0 (en) AKT INHIBITOR
IL285118A (en) Compounds and uses thereof
EP3967649C0 (en) LIPID NANOPARTICLE
DK3892621T3 (da) Haloallylaminforbindelser og anvendelse deraf
EP3742771C0 (en) M2M SM-SR TO SM-DP NOTIFICATION
DK4043460T3 (da) Antiproliferationsforbindelser og anvendelser deraf
EP3912517C0 (en) FRAME
DK3919498T6 (da) Pyrrolopyrimidinderivat og anvendelse deraf
EP3973348A4 (en) HEAD MOUNT DISPLAYS
EP3957391C0 (en) AGITATOR
DK3932909T3 (da) Benzoindazolonforbindelse og mellemprodukt heraf
DK3966226T3 (da) Masp-hæmmende forbindelser og anvendelser deraf
EP3975220A4 (en) Display panel
DK3573611T3 (da) Amidforbindelser og anvendelse deraf
EP3965638C0 (en) VAGINAL SPECULUM